Abstract
In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.
Original language | English (US) |
---|---|
Pages (from-to) | 327-329 |
Number of pages | 3 |
Journal | Bone Marrow Transplantation |
Volume | 30 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2002 |
Keywords
- Bullous pemphigoid
- Daclizumab
- GVHD
- Rituximab
- Transplantation
ASJC Scopus subject areas
- Hematology
- Transplantation